Apnimed, Inc. (APMD)
| Market Cap | 1.58B |
| Revenue (ttm) | 120.15M +11,915.0% |
| Net Income | -31.83M |
| EPS | -6.28 |
| Shares Out | 55.42M |
| PE Ratio | 4.19 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 433,783 |
| Open | 31.87 |
| Previous Close | 32.03 |
| Day's Range | 28.39 - 31.97 |
| 52-Week Range | 16.12 - 35.29 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 1, 2026 |
About APMD
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Financial Performance
In 2025, Apnimed's revenue was $38.47 million, an increase of 380.12% compared to the previous year's $8.01 million. Losses were -$128.19 million, 15.2% more than in 2024.
Financial StatementsNews
Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization...
Apnimed opens at $22.00, IPO priced at $16.00
Apnimed (APMD) priced 12M shares at $16.00. The deal size was increased to 12M shares from 10M shares of common stock and priced at the high-end of the $14.00-$16.00 range.
Apnimed 12M share IPO priced at $16.00
The deal size was increased to 12M shares of common stock from 10M shares of common stock and priced at the high-end of the $14.00-$16.00 range. BofA, Evercore ISI, Cantor…
Sleep apnea pill developer Apnimed targets $608 million valuation in US IPO
Late-stage drug developer Apnimed is targeting a valuation of up to $608 million in its initial public offering in the United States.
Sleep apnea pill maker Apnimed files for US IPO as biotech market revives
Apnimed, a late-stage clinical pharmaceutical company, filed for an initial public offering in the U.S. on Friday.
Apnimed IPO Registration Document (S-1)
Apnimed has filed to go public with an IPO on the NASDAQ